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Abstract: Diverse iridium peptide bioconjugates and the
corresponding iridium/gold bimetallic complexes have been
synthesized starting from a cyclometallated carboxylic acid
substituted IrIII complex [Ir(ppy)2(Phen-5-COO)] by solid
phase peptide synthesis (SPPS). The selected peptide se-
quences were an enkephalin derivative Tyr-Gly-Gly-Phe-Leu
together with the propargyl-substituted species Tyr-Gly-Pgl-
Phe-Leu to allow gold coordination (Pgl: propyrgyl-glycine,
HC/C-Gly), and a specific short peptide, Ala-Cys-Ala-Phen,
containing a cysteine residue. Introduction of the gold
center has been achieved via a click reaction with the alkyn-
yl group leading to an organometallic Au@C(triazole) species,
or by direct coordination to the sulfur atom of the cysteine.
The photophysical properties of these species revealed pre-
dominantly an emission originating from the Ir complex,
using mixed metal-to-ligand and ligand-to-ligand charge
transfer excited states of triplet multiplicity. The formation of
the peptide bioconjugates caused a systematic redshift of
the emission profiles. Lysosomal accumulation was observed
for all the complexes, in contrast to the expected mitochon-
drial accumulation triggered by the gold complexes. Only
the cysteine-containing Ir/Au bioconjugate displayed cyto-
toxic activity. The absence of activity may be related to the
lack of endosomal/lysosomal escape for the cationic peptide
conjugates. Interestingly, the different coordination sphere
of the gold atom may play a crucial role, as the Au@S(cys-
teine) bond may be more readily cleaved in a biological en-
vironment than the Au@C(triazole) bond, and thus the Au
fragment could be released from or trapped in the lyso-
somes, respectively. This work represents a starting point in
the development of bimetallic peptide bioconjugates as
theranostics and in the knowledge of factors that contribute
to anti-proliferative activity.
Introduction
In recent years heterometallic species have been identified as
emerging tools for theranosis.[1] Typically, such compounds are
formed by two distinct metallic fragments connected through
a linker, where each of the fragments is specifically designed
for either cell imaging or therapeutic applications. Examples of
this type of compounds were pioneered and developed by
Gimeno and Fern#ndez-Moreira,[2] Casini,[3] Patra,[4] or Gornitz-
ka,[5] among others. The examples from those groups basically
rely on ReI, RuII and EuIII complexes as luminescent probes,
combined with the well-established bioactivity of AuI (Aurano-
fin), RuII (NAMI-A) and PtII (Cisplatin) analogues. Luminescent
transition metal complexes have some advantages for life sci-
ence applications over the more commonly used organic dyes.
Their superior physicochemical properties (higher photostabili-
ty, larger Stokes shifts and long-lived excited states, often com-
bined with high quantum efficiencies) make them optimal can-
didates for cellular imaging techniques. In particular, ReI, RuII,
and IrIII derivatives were investigated for this purpose. Ortho-
metallated IrIII complexes of the type [Ir(N C)2(N N)]
+ , where N C
represents a phenyl pyridine (ppy) and N N a bisimine ligand
are highly luminescent species with demonstrated superior ca-
pability for cellular imaging.[6] However, one of the drawbacks
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of such cyclometallated iridium species is their poor aqueous
solubility, which could be overcome with the introduction of
biological vectors. To this end, peptides,[7] polyether chains
(PEG)[8] or cell penetrating peptides (CPP)[9] have been used to
maximize solubility and cell permeability of organometallic IrIII
complexes. Of these, peptides are particularly versatile. Metal–
peptide conjugates in general are gaining importance in bio-
chemical and pharmaceutical studies·[10] At the moment, a sig-
nificant number of peptides conjugated with bioactive com-
pounds have been explored as chemotherapeutics or radiola-
bels.[11]
Extending this approach to heterobimetallic compounds
with potential for theranostic applications we surmised that
peptides would make ideal linkers between both, the emissive
and bioactive metallic fragments. In this way the new bimetal-
lic molecules will be gaining not only water solubility but also
advantageous biological targeting/transport capacity as well as
the possibility of triggering a biological response. Building on
prior experiences in our groups, we decided to combine an
emissive IrIII fragment with bioactive AuI derivatives around
suitable peptide backbones. A few AuI–peptide species were
reported in the literature by the Metzler-Nolte and Gimeno
groups with excellent antitumor activities, see Figure 1.[12] Over
and beyond those, and to the best of our knowledge, there is
no mention of Au/Ir heterometallic theranostic agents.
Results and Discussion
Leu-enkephalin (Leu-Enk) is a pentapeptide (Tyr-Gly-Gly-Phe-
Leu) that binds to the opiate receptors in the central nervous
system. It has potential as biotherapeutic agent but its applica-
tion is dramatically hindered by rapid metabolism/degradation
and low bioavailability after administration because the penta-
peptide itself is unable to cross the blood–brain barrier
(BBB).[13] We have reported the first organometallic derivatives
of enkephalin,[14] some of which showed enhanced permeation
of the BBB due to the attachment of lipophilic metal com-
plexes.[15] More recent studies suggest that the combination of
opioid derivatives with anticancer agents could generate a
positive synergy effect onto the overall anticancer activity.[16, 12c]
In addition to that, it is known that some carcinomas such as
colorectal and pulmonary[17] cancer contain high levels of
opioid peptides and their corresponding membrane-bound
opioid receptors. In these cases, cancer cell recognition and
cellular uptake of drugs will be facilitated when the actual anti-
cancer drugs are combined with opioid peptides.[18]
In general, small peptides are best prepared via stepwise
amino acid incorporation by solid phase peptide synthesis
(SPPS).[19] One of the main challenges in the synthesis of metal
bioconjugates is the chemoselective insertion of the metal,
keeping in mind that some metal complexes may not be com-
patible with the conditions of SPPS, and more specifically
cleavage from the resin as the last synthesis step. The chemo-
selectivity issue is obviously aggravated when two different
metal complexes are to be inserted, both in a regio- and che-
moselective manner. In this work, the Ir fragments were linked
to the peptide via amide bonds using a carboxylic acid-func-
tionalized diimine ligand, and we chose alkynyl groups as han-
dles for insertion of the Au fragment since these provide a
means for mild, biorthogonal functionalization of the peptides
during as well as after SPPS. Alkynyl gold(I) complexes have re-
cently shown promise as metallodrug candidates with poten-
tial application as anticancer agents.[20] In this work, we intro-
duced the unnatural amino acid propargyl glycine (Pgl) as the
alkyne handle for Au conjugation.
The carboxylate-functionalized Ir complex [Ir(ppy)2(Phen-
COO)] (1) (ppy = 2-(2-pyridinyl-kN)phenyl-kC) was prepared fol-
lowing the reaction sequence depicted in Scheme 1. The car-
Figure 1. Gold(I) peptide derivatives A, B, C and D.[12] Scheme 1. Synthetic procedure for the preparation of complex 1.




boxylate-functionalized phenanthroline ligand, phen-5-CO2Na,
was synthesized by a modified literature procedure and react-
ed with the dimeric IrIII complex [Ir(ppy)2Cl]2 to yield 1 in 92 %
yield. No attempt was made to separate the possible stereoiso-
mers, as is also seen and described in the solid state structure
of 1 (below).
Suitable crystals of 1 for X-ray diffraction were obtained by
slow diffusion of diethyl ether into a dichloromethane solution
of 1. The molecule crystallizes in the space group P21/n. The
asymmetric unit is formed by one molecule of 1 and two mol-
ecules of dichloromethane from the crystallization solvent.
Four molecules of 1, specifically two of each enantiomer, are
present in the unit cell. As expected for these type of iridium
complexes, the phenylpyridine ligands are coordinated to the
metal center in a way that both pyridyl nitrogen atoms are
trans to each other.[21] Consequently, the phenyl carbon centers
are trans to the phenanthroline derivative thereby completing
octahedral coordination sphere around the IrIII metal center.
Moreover, their trans influence renders longer Ir@N bond
lengths for phenanthroline ligand in comparison with that
seen for the Ir@N bond lengths in the phenylpyridine
(Figure 2). Distortion from the ideal octahedral disposition is
mainly imposed by the phenanthroline bite angle, which
forces an N(4)-Ir-N(3) angle of 78.1(5)8 instead of the ideal 908.
The molecular structure together with selected bond distances
and angles are presented in Figure 2 and Table S1 (Supporting
Information).
We first established that Ir complex 1 was indeed a suitable
building block for peptide synthesis. The pentapeptide Leu-
Enk with the primary sequence Tyr-Gly-Gly-Phe-Leu was syn-
thesized by solid phase peptide synthesis (SPPS), specifically
the standard Fmoc-SPPS method.[22] This synthetic method pro-
vides a peptide sequence after the stepwise addition and cou-
pling of N-protected amino acids to an insoluble polymer, in
this specific case to a Wang resin. Each new amino acid will
face a synthetic cycle consisting of: i) cleavage of the N-pro-
tecting group of the amino acid anchored on the resin (depro-
tection step), ii) activation and coupling of the second N-pro-
tected amino acid, and iii) cleavage of the full peptide from the
resin when the peptide sequence is complete.
Thus, in this specific case, the resin already loaded with the
first amino acid (Fmoc-Leu) was subjected a Fmoc deprotec-
tion using 20 % of piperidine in DMF. Thereafter, Fmoc-Phe was
added together with the activators, TBTU (2-(1H-benzotriazole-
1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate) and HOBT
(hydroxybenzotriazole), as well as di-isopropyl-ethylamine
(DIPEA) as base in DMF affording the successful coupling reac-
tion to the N-terminal leucine. This process was repeated with
two subsequent glycines and the N-terminal tyrosine. Eventual-
ly, Ir complex 1 was coupled to the N-terminal amino group
after Fmoc deprotection as if it were one additional amino
acid. After cleavage from the resin by treatment with 95 % of
TFA (trifluoroacetic acid), 2.5 % TIPS (triisopropylsilane) and
2.5 % H2O conjugate 2 was obtained successfully, see
Scheme 2. Purification by semipreparative HPLC led to the de-
sired compound in 7 % overall yield starting from the Fmoc-
Phe-loaded Wang resin. MALDI mass spectrometry clearly
showed the cation molecular peak at m/z = 1262.4, which
agrees completely with the calculated value for [M-TFA]
(C66H61IrN9O8).
After the success of the synthesis of the iridium peptide bio-
conjugate, it is necessary to introduce a functionalization in
one of the amino acids to allow coordination of a gold center.
For this we have chosen alkynyl groups since these provide a
means for mild, biorthogonal functionalization of the peptides
Figure 2. POV-ray view of one of the molecules present in the asymmetric
unit of complex 1. Most relevant bond distances (a) and angles (8): Ir(1)@
C(11) 2.008(14), Ir(1)@C(22) 2.008(12), Ir(1)@N(1) 2.048(11), Ir(1)@N(2) 2.033(11),
Ir(1)@N(3) 2.143(11), Ir(1)@N(4) 2.155(11); N(1)-Ir(1)-N(2) 173.5(4), N(4)-Ir(1)-
N(3) 78.1(5).
Scheme 2. Representation of solid phase peptide synthesis (SPPS) of com-
pound 2.




during as well as after SPPS. Consequently, we introduced the
unnatural amino acid propargyl glycine (Pgl) as the alkyne
handle for Au conjugation.
For the synthesis of compound 3, the Fmoc-SPPS method
was used as described for complex 2, with the introduction of
Pgl as the third amino acid, replacing a glycine residue. As the
last step, the luminescent IrIII complex 1 was coupled to the N-
terminal tyrosine. Cleavage of the bioconjugated organometal-
lic IrIII species from the resin afforded conjugate 3 (Figure 3).
The resulting solid was purified by column chromatography
using a mixture of CH2Cl2 :MeOH (10:2) as eluent. Mass spec-
trometry (MALDI-MS) confirmed the expected structure. A
peak for the molecular ion [M-TFA] at m/z = 1300.4267 was ob-
served that perfectly matches the calculated mass for
(C66H61IrN9O8).
Thereafter, different methods were explored to coordinate
the triphenylphosphine gold(I) fragment to the alkynyl group.
In an effort to obtain a Au-alkynyl species of the type Ph3PAu-
C/C-R directly, bases such as K2CO3, DIPEA or KOH in different
solvents (dichloromethane, dimethylformamide and methanol)
with [AuClPPh3] were tried, but did not afford the desired com-
pound. A similar result was obtained when [Au(acac)PPh3] was
used in either methanol or dichloromethane. Eventually, the
use of [AuN3PPh3] as the gold(I) source allowed a (3 + 2) cyclo-
addition reaction (“click” reaction) to take place affording a Au-
substituted triazole (Scheme 3).[23, 12b] The reaction mechanism
is not entirely known[23] but a mechanism similar to that origi-
nally proposed by Sharpless and Fokin for the classical Cu-as-
sisted azide-alkyne cycloaddition reaction (Cu-AAC) is as-
sumed.[24] All spectroscopic data confirm the successful forma-
tion of the bimetallic peptide, with the Au bound to the Pgl
side chain. Compound 4 was purified by HPLC, The 31P{1H}
NMR spectrum showed a single signal at 43.4 ppm in DMSO
characteristic for the P-Au-C(triazole) unit (shifted from 31 ppm
for the starting material Au azide). Moreover, a peak at mass
m/z = 1801.7648 observed by MALDI-MS that matches the
mass of the molecular ion (C84H76AuIrN12O8P)
+ was also ob-
served. These results are in agreement with data reported by
Metzler-Nolte and co-workers for similar reactions.[12b]
In order to explore alternative links of the Au fragment to
the peptide side chain a peptide sequence containing a cys-
teine residue within the structure was synthesized and its coor-
dination to the Ph3PAu fragment explored. Specifically, a short
peptide with the Ala-Cys-Ala-Phe sequence was chosen, where
the N-terminal alanine would be conjugated to the iridium
fragment as for 4, and the Au fragment would be linked to the
cysteine sulfur atom. Handling cysteine residues has an added
difficulty because of the potential oxidation of the sulfur atom,
therefore, a thiol protected cysteine residue, S-Trityl-cysteine,
was used for the stepwise solid-phase peptide synthesis
(SPPS). In a similar procedure as described before the desired Ir
peptide bioconjugate still bonded to the resin was prepared.
Scheme 4 shows the specific peptide sequence containing the
protected cysteine, and the possible approaches for binding
the gold center to the peptide. Two pathways are conceivable
to yield the desired heterobimetallic complex 5. In the first
place, thiol deprotection followed by coordination of the gold
fragment and finally cleavage from the Wang resin as the final
step might yield conjugate 5. Alternatively, cleavage of the iri-
dium peptide from the resin could be the first step, with con-
comitant removal of the thiol-protecting trityl group, followed
by coordination of the gold fragment to the cysteine sulfur
Figure 3. Chemical structure of compound 3 obtained by SPPS.
Scheme 3. Synthetic procedure of complex 4.
Scheme 4. Depiction of the synthetic pathways to obtain compound 5. Re-
action conditions: i) DCM/TFA/TIS (90/5/5); ii) TFA/TIS/H2O (95/2.5/2.5);
iii) [AuClPPh3] , DIPEA, DCM followed by TFA/DCM/Phenol (50/40/10);
iv) [AuClPPh3] , DIPEA, DCM.




atom. Attempts to obtain compound 5 by the first pathway
however only led to decomposition of the product, possibly
because cleavage conditions were too harsh for the S-AuPPh3
fragment, as have been previously observed by us in gold thio-
late amino acid systems if mild conditions were not used.[12f] In
contrast, when the second synthetic pathway was used, com-
pound 5 was cleanly obtained after purification by HPLC.
MALDI mass spectrometry was used once more to corroborate
the successful synthesis and the molecular peak was observed
at 1575.6 m/z, which agrees with the calculated value for
C71H62AuIrN8O6PS
+ (1575.4).
Absorption and emission spectroscopy
UV/Vis absorption spectra of complexes 1–5 were recorded in
DMSO solution at 298 K and the most relevant data are sum-
marized in Table 1. The absorption spectra for all the com-
pounds presented a similar pattern with a highly intense ab-
sorption band around 265 nm and a set of weaker bands in
the region between 370–500 nm (see Figure S1). The higher
energy bands around 265 nm with extinction coefficients in
the order of 104 dm3 mol@1 cm@1 can be attributed to a spin al-
lowed ligand centered (1LC) transition, p!p* transition, mainly
within the ppy and phen ligands.[25] Then, at lower energy (l>
370 nm) charge transfer transitions are observed. The nature of
these transitions is not well defined, and assumed to corre-
spond to a mixture of ligand-to-ligand-charge transfer (LLCT)
transitions from the ppy to phen derivative, and to a metal-to-
ligand-charge transfer (MLCT) transition from iridium to the dii-
mine ligand.[26] This type of transition has been previously de-
scribed as metal-ligand-to-ligand charge transfer (MLLCT) tran-
sition, specifically as a dpIr-C!p*N N transition.[27] In this particu-
lar case, it can be suggested that bands from 375 to 415 nm,
whose e is in the range of (1–10) V 103 m@1 cm@1, originate from
spin-allowed 1MLLCT transitions. Alternatively, lowest energy
lying bands (>415 nm) with small molar absorption coefficient
(e <103 m@1 cm@1) are ascribed to spin-forbidden 3MLLCT transi-
tions.[26] Despite the fact that in this specific case those bands
are not clearly observed due to the small e, they can be sur-
mised, Figure S1. Emission and excitation spectra were also re-
corded for complexes 1–5 in DMSO solution, see Table 1 and
Figure 4. Upon irradiation all complexes showed a broad emis-
sion around 582 nm for complex 1 and around 615 nm for the
bioconjugated species, respectively. This redshift can be attrib-
uted to the electron-withdrawing amide substituent that sta-
bilises the p* orbitals of the diimine. However, the presence of
the gold fragment does not seem to affect the emissive behav-
iour of the complexes. In all cases this emission is associated
to 3MLCT (dpIr-C!p*N N) transition and a 3LLCT pppy!p*N N by
comparison with similar iridium structures.[28] In addition, the
quantum yields for emission were also determined in aerated
DMSO at room temperature by an absolute method. For all
complexes, quantum yields ranging from 13 to 21 % were ob-
served. Interestingly, the bimetallic Ir/Au complexes had slight-
ly higher values around 20 %.
Cytotoxic activity
The antiproliferative activity of 1, 2, 4, and 5 was determined
by the MTT assay in the lung cancer cell line A549. All com-
plexes were incubated for 24 hours with the tumor cell line up
to a maximal concentration of 50 mm. Neither the bioconjugat-
ed iridium compound 2, nor the parent complex 1 showed cy-
totoxicity up to the studied concentration, see Table 2. Surpris-
ingly, the bimetallic bioconjugated compound 4 did not show
cytotoxic activity, which is quite unexpected for a gold deriva-
tive. On the other hand, compound 5 displayed an antiprolifer-
ative effect with IC50 = 12:1.8 mm, see Table 2. This result dem-
onstrates the importance of the direct gold coordination
sphere for cytotoxicity. Here, the S-Au-P unit shows markedly
higher cytotoxicity than the Au-C-triazol species with a C-Au-P
unit. A plausible explanation could be related with the
Table 1. Absorption, emission, excitation and quantum yields of com-
plexes 1–5 measured in DMSO at 298 K.
UV/Vis
(V 103 e [dm3 mol@1 cm@1])
lem (lexc) [nm] Ø
1 266 (48.3), 374 (6.3), 415 (3.2) 582 (443) 17
2 267 (56.2), 375 (6.9), 417 (3.3) 616 (433) 13
3 269 (38.6), 378 (5.5), 416 (2.9) 617 (426) 13
4 266 (26.6), 381 (3.4), 416 (1.8) 613 (375) 21
5 267 (16.9), 382 (2.4), 416 (1.2) 613 (385) 19
Figure 4. Emission spectra of complexes 1–5 recorded in DMSO and RT.
Table 2. IC50 values on A549 cells of 1–2 and 4–5 measured by the MTT
assay after 24 h.







[a] Analyzed concentrations ranged from 1.25 to 50 mm, data are average
+ /-SD of 3 independent measurements each one for quadruplicate. (Aur-
anofin IC50 = 7.59 mM in A549, 24 h)
[31]




strength of the bond between Au@S and Au@C, being higher
in the latter and preventing the metal center to react so easily
with their biological targets. A comparison with the cytotoxici-
ty of the reference Cisplatin complex in the same conditions
114.2:9.1 mm,[29] although measured in water, revealed a
much higher activity for the bioconjugate complex 5. It is
worth mentioning that all bioconjugated complexes 2–5 had
better solubility in the biological media than the parent 1 com-
plex, demonstrating the expected positive effect of introducing
the peptide.
Moreover, as many gold complexes have been reported to
induce oxidative stress,[30] the possible generation of reactive
oxygen species (ROS) was analyzed for complex 5 by flow cy-
tometry. Indeed, Figure 5 clearly shows an increment on the
generation of ROS for those cells treated with complex 5.
Cell imaging
The metal-peptide bioconjugated complexes prepared here
have the appropriate luminescent properties, with strong emis-
sion around 615 nm, to elucidate their cellular distribution by
fluorescence cell microscopy. Specifically, A549 cells were incu-
bated with the complexes at a concentration of 25 mm and co-
localization was investigated with MitoTracker and LysoTracker,
to detect mitochondrial or lysosomal localization, respectively.
After 24 h of incubation, cells were irradiated at 473 nm to
reveal the localization of the complexes, see Figures 6, Figure 7
and S2. Both MitoTracker and LysoTracker can be visualized
after irradiation at 588 nm. Also, superimposition images of
metal complexes and cellular localization dyes are shown in
Figure 6 and Figure 7. In Figure 6, the colocalization for the
monometallic Ir conjugate 2 and the bimetallic Ir/Au bioconju-
gate 4 is investigated. Localization of the complexes was seen
in specific spots inside the cytoplasmic area of the cells, close
to the nucleus but without penetrating the nuclear membrane.
As can be clearly seen from the superimposition images, no lo-
calization of the bioconjugates occurs in mitochondria. Also
for higher concentrations, a precipitate was found outside the
cells, indicating that the complexes were not completely solu-
ble (Figure 6).
This result is surprising, not only because some cyclometal-
lated iridium complexes were shown to specifically target mi-
tochondria,[32] but also because mitochondria are a well-known
biological target for gold compounds.[33] However, the addition
of a peptide surely affects the interaction of the cyclometallat-
ed complex with the cell from the very beginning, possibly di-
recting their internalization mechanism already, which might
be eventually reflected on their biodistribution.
Interestingly, a more distinct localization of the conjugates
was detected in lysosomes, through good overlay with the Ly-
soTracker dye with Pearson coefficients ranging from 0.8–0.9.
Figure 7 show the images for the bimetallic species 4 and 5
and S2 for the monometallic complex 2. Such localization has
already been reported for some neutral[34] and cationic[35] cyclo-
metallated IrIII complexes, all of them containing protonatable
basic substituents.[36] Lysosomes are known to be more acidic
organelles compared with cytoplasm or other subcellular com-
partments (pH 5.0–5.5 vs. 7.4 respectively). Thus, the presence
of protonatable basic substituents, as in this case N-amide
group, could be facilitating the lysosomal localization. Velders
and co-workers have described a series of cyclometallated IrIII
derivatives containing three lysine residues that localized in
the lysosomes.[37] Furthermore, other cyclometallated IrIII deriv-
atives containing cationic peptides were also described to ac-
cumulate in lysosomes,[38] which agrees with the pattern ob-
served in this case.
Figure 5. Flow cytometry analysis of ROS production induced by 5.
Figure 6. Fluorescence microscopy images from colocalization experiments
of complexes 2 and 4 (green) with MitoTracker incubated with A549 cells. (A
and A’) superimposition images. (B and B’) superimposition images including
the phase contrast.




Interestingly, the lack of cytotoxic activity of these monome-
tallic or bimetallic peptide bioconjugates may be related to
the inability of the cationic complexes for a lysosomal escape.
This situation appears somewhat different for the neutral bi-
metallic bioconjugate with a cysteine moiety, which is the only
one with cytotoxic activity. Localization of this derivate is also
observed in the lysosomes but a slow escape of the whole
compounds may be possible or/and the gold phosphine frag-
ment is slowly released from the peptide and translocates to
mitochondria, which naturally would not be detectable by
fluorescence microscopy. The higher strength of the Au@C
bond in comparison with that of Au@S could be preventing
such release from the lysosomes and eventually inhibiting the
cytotoxicity of compound 4.
Conclusions
Solid phase peptide synthesis (SSPS) was used to prepare small
peptides which were further linked to either a luminescent iri-
dium(III) fragment or both, luminescent iridium(III) and bioac-
tive gold(I) fragments. The iridium fragment was functionalized
with a carboxylic acid group on a phenanthroline ligand, and
bioconjugated to the N-terminal amino group of three differ-
ent peptides in the last step of an SPPS Scheme. For the Au
fragment, two different biorthogonal conjugation strategies
were explored. For one, the gold fragment was attached via a
cycloaddition reaction of a gold azido derivative to the triple
bond of propargyl-glycine, affording a C-coordinated Au-tria-
zole derivative 4. Alternatively, the Au fragment could be suc-
cessfully bound to the sulfur atom of a cysteine residue 5. The
excellent luminescence properties of the Ir fragment translated
into the bioconjugates as well, which presents red shifted
emissions and quantum yields around 20 %. All compounds
could be readily tracked inside A549 lung cancer cells. Lysoso-
mal localization after 24 h was confirmed by co-staining with
LysoTracker Red, which is consistent with an uptake mecha-
nism through lysosomes, and the fact that this is still observa-
ble even 24 h after incubation is indicative for a very slow lyso-
somal escape for these conjugates. Mitochondrial activity, for
example, through inhibition of mitochondrial thioredoxin re-
ductase, is believed to be the mechanism of action of Au anti-
cancer drug candidates.[31] Surprisingly, no mitochondrial locali-
zation was observed, despite the fact that this has been ob-
served for large lipophilic cations (LLCs),[39] such as the Ir frag-
ment, as well as for small molecule Au anticancer drug candi-
dates. Interestingly, the lack of significant mitochondrial
localization might correlate with the low anti-proliferative ac-
tivity of our metal-peptide conjugates: Only the heterobimetal-
lic complex 5 presented significant activity towards the A549
lung cancer cells, all other compounds were inactive up to a
concentration of 50 mm. While a complete elucidation of the
exact course of action would require significantly more experi-
ments, this lack of activity may well have to do with lack of en-
dosomal/ lysosomal escape for the (positively charged) peptide
conjugates. Also, the strength of the Au–ligand bond may play
a crucial role in that it is more readily cleaved in a biological
environment for 5, having an Au-S bond. The Au@C(triazole)
bond in 4 is presumably more stable, and thus the Au frag-
ment will be more reliably remain linked to the peptide, which
in turn is trapped in lysosomes. This work therefore provides
crucial insight into the factors that contribute to anti-prolifera-
tive activity of generally toxic metal fragments in bioconju-
gates. While chemical tools and reactions exist to link metal
fragments to selected sites in peptides almost at will, the exact
choice of linker and the resulting coordination environment
crucially contribute to the overall activity of the conjugate.
Experimental Section
General measurements and analysis instrumentation : Mass spec-
tra were recorded on a Bruker Esquire 3000 PLUS, with the electro-
spray (ESI) technique and on a Bruker Microflex (MALDI-TOF). 1H,
13C{1H} and 31P{1H} including 2D experiments, were recorded at
room temperature on a Bruker Avance 400 spectrometer (1H
400.0 MHz, 13C 100.6 MHz, 31P 162.0 MHz) or on a Bruker Avance II
300 spectrometer (1H 300.0 MHz, 13C 75.5 MHz, 31P 121.5 MHz) with
chemical shifts (d, ppm) reported relative to the solvent peaks of
Figure 7. Fluorescence microscopy images from colocalization experiments
of complexes 4 and 5 (green) with LysoTracker incubated with A549 cells. (A
and A’) superimposition images. (B and B’) superimposition images including
the phase contrast.




the deuterated solvent. All J values are given in Hz. IR spectra were
recorded in neat samples on a PerkinElmer Spectrum 100FT-IR
spectrometer. Room temperature steady-state emission and excita-
tion spectra were recorded with a Jobin–Yvon-Horiba Fluorolog
FL3-11 spectrometer. UV-vis spectra were recorded with 1 cm
quartz cells on an Evolution 600 spectrophotometer. Quantum
yields were measured in using an absolute method provided by
Hamamatsu Photonics Quantaurus-QY C11347-11. Specifically, each
sample was measured using the excitation scanning mode in aerat-
ed DMSO solution at rt, after recording a reference sample (neat
aerated DMSO at rt). Excitation of the samples was made from 350
to 470 nm in 10 nm intervals. The quantum yield value given is the
one obtained at maxima intensity excitation, that is, 1 (440 nm), 2
(430 nm), 3 (380 nm), 4 (390 nm), 5 (440 nm) The experiment was
repeated three times to ensure reproducibility.
Semi-preparative HPLC purifications and analysis were performed
on a Knauer HPLC system using either one of the following col-
umns: Macherey–Nagel VP 125/10 Nucleodur 100-5 C18ec for pu-
rification and Macherey–Nagel EC 125/4 Nucleodur C18 Pyramid
5 mm or Agilent ZORBAX Eclipse XDB-C18 4.6 V 150 mm for analy-
sis.
Crystal structure determination : Crystals were mounted in inert
oil glass fibres and transferred to the cold gas stream of an SMART
APEX diffractometer equipped with a low-temperature attachment.
Data were collected using monochromated Mo Ka radiation (l=
0.71073 a). Scan type w. Absorption corrections based on multiple
scans were applied with the program SADABS.[40] The structures
were solved by direct methods and refined on F2 using the pro-
gram SHELXL-2016.[41] All non-hydrogen atoms were refined aniso-
tropically. In most of the cases, hydrogen atoms were included in
calculated positions and refined using a riding model; some of the
hydrogen atoms have been located in the diffraction map. Refine-
ments were carried out by full-matrix least-squares on F2 for all
data.
Deposition Number 1980164 contain(s) the supplementary crystal-
lographic data for this paper. These data are provided free of
charge by the joint Cambridge Crystallographic Data Centre and
Fachinformationszentrum Karlsruhe Access Structures service
www.ccdc.cam.ac.uk/structures.
Antiproliferative studies : MTT assay. Exponentially growing cells
(A549) were seeded at a density of approximately 104 cells per well
in 96-well flat-bottomed microplates and allowed to attach for
24 h prior to addition of compounds. The complexes were dis-
solved in DMSO and added to cells in concentrations ranging from
50 to 0.5 mm in quadruplicate. Cells were incubated with our com-
pounds for 24 h at 37 8C. Ten microliters of MTT (5 mg mL@1) were
added to each well and plates were incubated for 2 h at 37 8C. Fi-
nally, the growth media was eliminated and DMSO (100 ml per
well) was added to dissolve the formazan precipitates. The optical
density was measured at 550 nm using a 96-well multiscanner au-
toreader (ELISA). The IC50 was calculated by nonlinear regression
analysis.
ROS determination by flow cytometry : Exponentially growing
cells (A549) were seeded at a density of approximately 5 V 105 cells
per well in 6-well flat-bottomed plates and allowed to attach for
24 h prior to addition of the compound. Complex 5 was dissolved
in DMSO and added to cells up to concentrations of 9.8 and
7.4 mm in duplicate. Cells were incubated with the complex for
48 h at 37 8C. The medium was removed and they were trypsi-
nized. Thereafter the CellROXSGreen Flow cytometry assay kit (Mo-
lecular Probes, C10493) was used to evaluate the generation of
ROS in a Gallios Flow Cytometer (Beckman Couter).
Cell fluorescence microscopy study : European Collection of Cell
Cultures were maintained in Hepes modified minimum essential
medium (DMEM) supplemented with 5 % fetal bovine serum, peni-
cillin, and streptomycin. A549 cells were detached from the plastic
flask using trypsin-EDTA solution and suspended in an excess
volume of growth medium. 300 ml of a homogeneous cell suspen-
sion was then distributed into m-slide 8 well ibiTreat they were al-
lowed to attach for 24 h prior to addition of compounds. Then,
200 ml of culture medium was removed and 100 ml of a solution of
the corresponding complexes were added to the cells up to a final
concentration of 19 or 25 mm. The complexes were incubated with
the cells for 24 h at 37 8C. Thereafter, 50 ml of MitoTracker Red or
LysoTracker red-DND-99 was added up to a final concentration of
10 nm. They were incubated with the cells for 15 min (MitoTracker)
or 30 min (LysoTracker) at room temperature. Eventually the
medium was replaced with fresh medium without phenol red.
Preparations were viewed using an Olympus FV10-i Oil type com-
pact confocal laser microscope using a V 10 or V 60 objective, with
excitation wavelength at 473 and 559 nm.
Materials and procedures : The starting materials [AuCl(tht)] ,[42]
[Au(acac)PPh3] ,
[43] [AuClPPh3] ,
[44] and [AuN3PPh3] ,
[23] were prepared
according to published procedures. IrCl3·n H2O was purchased from
Strem Chemicals and used as received. Fmoc-protected amino
acids and resins for SPPS were purchased from Novabiochem. All
other reagents were commercially available and were used without
further purification. Solvents were dried with a SPS solvent purifica-
tion system. 1H, 13C{1H} NMR spectra, HR-MALDI spectra and HPLC
Chromatograms can be consulted in the ESI.
Synthesis of complex 1: [Ir(m-Cl)(ppy)2]2 (1 equiv, 536.5 mg,
0.499 mmol), sodium 1,10 phenanthroline-5-carboxylate
(2.28 equiv, 281 mg, 1.14 mmol) and sodium carbonate (19.1 equiv,
780 mg, 9.51 mmol) were suspended in a 1:1 mixture of DCM and
methanol (54 mL) and heated at 55 8C until consumption of the
limiting reagent (ca 2 h). The solvent was then evaporated and the
crude redissolved in DCM, filtrated over celite and washed with
water (2 V 15 mL). The organic phase was dried with anhydrous
magnesium sulphate and evaporated (233.2 mg, 92 %). 1H NMR
(300 MHz, DMSO): d 9.87 (dd, J = 8.6, 1.4 Hz, 1 H, H13 or H22), 8.87
(dd, J = 8.3, 1.4 Hz, 1 H, H13 or H22), 8.53 (s, 1 H, H17), 8.25 (d, J =
7.9 Hz, 2 H, H2 + H2’), 8.12 (dd, J = 5.0, 1.4 Hz, 2 H, H15 + H20), 8.00–
7.91 (m, 4 H, H8 + H8’ or H11 + H11’, + H14 + H21), 7.90–7.83 (m, tap,
J = 7.9 Hz, 2 H, H3 + H3’), 7.45 (tap, J = 6.0 Hz, 2 H, H9 + H9’ or H10 +
H10’), 7.11–6.84 (m, 6 H, H4 + H4’ + H5 + H5’ + H9 + H9’ or H10 +
H10’), 6.30 (d, J = 7.5 Hz, 2 H, H8 + H8’ or H11 + H11’).
13C NMR (75
MHz, DMSO): d 166.88 (s, C6 or C6’), 166.86 (s, C6 or C6’), 166.55 (s,
C25), 150.59 (s, C12 or C12’ or C7 or C7’), 150.29 (s, C12 or C12’ or C7 or
C7’), 149.71 (s, C15 or C20), 149.58 (s, C15 or C20), 148.99 (s, C9 or C9’ or
C10 or C10’), 148.95 (s, C9 or C9’ or C10 or C10’), 146.23 (s, C23 or C24),
145.66 (s, C23 or C24), 144.07 (s, C12 or C12’ or C7 or C7’), 144.05 (s, C12
or C12’ or C7 or C7’), 141.63 (s, C17), 139.53 (s, C13 or C22), 138.77 (s,
C13 or C22), 138.61 (s, C3 or C3’), 138.58 (s, C3 or C3’), 131.30 (s, C8 or
C8’ or C11 or C11’), 131.27 (s, C8 or C8’ or C11 or C11’), 130.71 (s, C16 or
C19), 130.66 (s, C16 or C19), 130.16 (s, 2C, C9 + C9’ or C10 + C10’),
126.74 (s, C14 or C21), 126.59 (s, C14 or C21), 125.99 (s, C17), 125.03 (s,
C8 or C8’ or C11 or C11’), 123.87 (s, C4 or C4’), 123.84 (s, C4 or C4’),
122.24 (s, 2C, C5 + C5’), 119.93 (s, 2C, C2 + C2’). IR (cm
@1): 3035
u(CAr-H), 1595, 1475 u(COO
@). HRMS (m/z): 725.1490 [M + H+] ,
C35H24IrN4O2 725.1525.
Synthesis of complex 2 : Solid-phase peptide synthesis was per-
formed manually in 5 mL plastic syringes with a porous disc as
filter. The peptide sequence (Tyr(tBu)-Gly-Gly-Phe) was assembled
on Fmoc-protected Leucine loaded Rink amide resin (Novabio-
chem, 362 mg, loading 0.69 mmol g@1) following general proce-




dure. Then 211.2 mg (0.06 mmol) of the peptide-loaded resin were
weighed and reacted with 1 (94 mg, 0.129 mmol), TBTU (41.7 mg,
0.129 mmol) and DIPEA (45.3 mL, 0.260 mmol) in DMF as an addi-
tional peptide coupling reaction for 4 h. The resin was then
washed twice with fresh DMF and the coupling step was repeated
with fresh reagents for 8 additional hours for 2 additional hours,
when finally, Kaiser Test confirmed that no free primary amines
were present on the resin. Cleavage was performed with TFA/TIS/
H2O (95/2.5/2.5) for 3 h, then precipitation in a mixture 1:1 of ice-
cold diethyl ether/hexane yielded the crude product, which was
purified by semi preparative HPLC. Fractions containing the pure
product were pooled, frozen in liquid nitrogen and lyophilized.
Yellow solid (11.21 mg, 7 %). HR-MALDI (m/z): 1262.4278 [M-TFA],
C63H59IrN9O8 1262.4111.
Synthesis of complex 3 : Solid-phase peptide synthesis was per-
formed manually in 5 mL plastic syringes with a porous disc as
filter. The peptide sequence (Tyr(tBu)-Gly-Pgl-Phe) was assembled
on Fmoc-protected Leucine loaded Rink amide resin (Novabio-
chem, 390.62 mg, loading 0.69 mmol g@1) following general proce-
dure for SPPS. Then 242.6 mg (0.205 mmol) of the peptide-loaded
resin were weighed and reacted with 39 (148.38 mg, 0.205 mmol),
TBTU (65.83 mg, 0.205 mmol), HOBT (27.7 mg, 0.205 mmol) and
DIPEA (71.4 mL, 0.41 mmol) in DMF as an additional peptide cou-
pling reaction overnight. The resin was then washed twice with
fresh DMF, and the coupling step was repeated with fresh reagents
for 8 additional hours, when finally a Kaiser Test confirmed that no
free primary amines were present on the resin. Cleavage was per-
formed with TFA/TIS/H2O (95/2.5/2.5) for 4 h 30, then precipitation
in a mixture 1:1 of ice-cold diethyl ether/hexane yielded the crude
product, which was purified by alumina column chromatography
using CH2Cl2/MeOH (10:2) as eluent. Yellow solid (21.65 mg, 11 %).
HR-MALDI (m/z): 1300.4267 [M-TFA], C66H61IrN9O8 1300.4267.
Synthesis of complex 4. 3 : (13.66 mg, 0.01 mmol) was dissolved in
DMF (2 mL) and DIPEA (1.7 mL, 0.01 mmol) followed by [AuN3PPh3]
(24.2 mg, 0.048 mmol) were added. The solution was stirred for 2
days, then the solvent was evaporated and the resulting solid was
washed twice with DCM. The crude product was was purified by
semi preparative HPLC. Fractions containing the pure product
were pooled, frozen in liquid nitrogen and lyophilized. Yellow solid
(3.81 mg, 20 %). MALDI (m/z): 1801.8 [M-TFA], C84H76AuIrN12O8P
1801.8.
Synthesis of complex 5 : The peptide sequence (Ala-Cys(Trt)-Ala)
was assembled on Fmoc-protected Phenylalanine loaded Rink
amide resin (Novabiochem, 308 mg, loading 0.65 mmol g@1) follow-
ing general procedure for SPPS. Then 190 mg (0.09 mmol) of the
peptide-loaded resin were weighed and reacted with 1 (124 mg,
0.17 mmol), TBTU (55.2 mg, 0.017 mmol), HOBT (23.2, 0.017 mmol)
and DIPEA (60 mL, 0.34 mmol) in DMF as an additional peptide cou-
pling reaction overnight. The resin was then washed twice with
fresh DMF and 1 TBTU and DIPEA were added again in DMF and
the syringe was placed on a shaker overnight, when finally, Kaiser
Test confirmed that no free primary amines were present on the
resin. Cleavage was performed with 3 mL of TFA/TIS/H2O (95/2.5/
2.5) for 3 h in a two-necked round bottom flask under argon at-
mosphere. The resulting solution containing iridium bioconjugate
was transferred to a weighed flask under argon via cannula. The
solvent was evaporated, and the weight of the crude was calculat-
ed in order to add an equimolar quantity of AuClPPh3 (20.4 mg,
0.041 mmol), DCM (10 mL) and K2CO3 in excess. After 1 night at r.t. ,
the mixture was filtered over celite, concentrated and precipitated
with ether. The crude product was then purified by semi prepara-
tive HPLC. Fractions containing the pure product were pooled,
frozen in liquid nitrogen and lyophilized. Yellow solid (6 mg, 2 %).
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